MX2009010894A - Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa. - Google Patents

Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.

Info

Publication number
MX2009010894A
MX2009010894A MX2009010894A MX2009010894A MX2009010894A MX 2009010894 A MX2009010894 A MX 2009010894A MX 2009010894 A MX2009010894 A MX 2009010894A MX 2009010894 A MX2009010894 A MX 2009010894A MX 2009010894 A MX2009010894 A MX 2009010894A
Authority
MX
Mexico
Prior art keywords
coa desaturase
hydroquinazolin
derivatives
stearoyl
stearoyl coa
Prior art date
Application number
MX2009010894A
Other languages
English (en)
Spanish (es)
Inventor
Jeff Zablocki
Dmitry Koltun
Eric Parkhill
Natalya Vasilevich
Jeffrey Chisholm
Melanie Boze
Andrei Glushkov
Andrew Cole
Elena Mayboroda
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of MX2009010894A publication Critical patent/MX2009010894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009010894A 2007-04-11 2008-04-10 Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa. MX2009010894A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91122507P 2007-04-11 2007-04-11
PCT/US2008/004632 WO2008127615A1 (en) 2007-04-11 2008-04-10 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS

Publications (1)

Publication Number Publication Date
MX2009010894A true MX2009010894A (es) 2009-10-26

Family

ID=39709340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010894A MX2009010894A (es) 2007-04-11 2008-04-10 Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.

Country Status (12)

Country Link
US (1) US20080255161A1 (enExample)
EP (1) EP2155695A1 (enExample)
JP (1) JP2010523674A (enExample)
KR (1) KR20100016421A (enExample)
CN (1) CN101652353A (enExample)
AU (1) AU2008239689A1 (enExample)
BR (1) BRPI0809551A2 (enExample)
CA (1) CA2683925A1 (enExample)
IL (1) IL201117A0 (enExample)
MX (1) MX2009010894A (enExample)
RU (1) RU2009141596A (enExample)
WO (1) WO2008127615A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003658A (es) * 2006-10-05 2009-04-22 Cv Therapeutics Inc Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
EP2131844A1 (en) * 2007-04-09 2009-12-16 CV Therapeutics Inc. PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
WO2009089277A2 (en) 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
EP2274308A1 (en) * 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
AU2009244664A1 (en) * 2008-04-04 2009-11-12 Gilead Sciences, Inc. Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
BR112014026266A2 (pt) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
KR20150003849A (ko) 2012-04-24 2015-01-09 추가이 세이야쿠 가부시키가이샤 퀴나졸린디온 유도체
CN105829285A (zh) * 2013-10-23 2016-08-03 中外制药株式会社 喹唑啉酮和异喹啉酮衍生物
PL3292116T3 (pl) 2015-02-02 2022-02-21 Valo Health, Inc. 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
CA3094527A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
AU2020299362A1 (en) * 2019-07-02 2022-02-24 Effector Therapeutics, Inc. EiF4e-inhibiting 4-OXO-3,4-dihydropyrido(3,4-d)pyrimidine compounds
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN110903253B (zh) * 2019-12-13 2020-12-25 西安交通大学医学院第一附属医院 一种喹唑啉酮类化合物及其制备方法和应用
CN113354590A (zh) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 拮抗nod1/2受体信号通路的喹唑啉酮类化合物
IN202011027502A (enExample) * 2020-06-29 2021-12-31 Council Scient Ind Res
EP4185380A4 (en) * 2020-07-24 2024-08-21 Inipharm, Inc. Quinazolinone hsd17b13 inhibitors and uses thereof
AU2021377248B2 (en) * 2020-11-13 2025-12-18 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS5920668B2 (ja) * 1975-10-03 1984-05-15 田辺製薬株式会社 キナゾリン誘導体の製法
JPS5920670B2 (ja) * 1976-04-10 1984-05-15 田辺製薬株式会社 キナゾリノン誘導体の製法
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
JP3488890B2 (ja) * 1993-11-09 2004-01-19 アグロカネショウ株式会社 ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
CA2201477C (en) * 1995-08-02 2005-05-03 Javier Bartroli New pyrimidone derivatives with antifungal activity
ID26984A (id) * 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6562830B1 (en) * 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003238157A1 (en) * 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
JP2006193426A (ja) * 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
JPWO2005051924A1 (ja) * 2003-11-28 2007-06-21 三菱ウェルファーマ株式会社 キナゾリン誘導体及びその製造方法
CA2580857A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
DK1830869T3 (da) * 2004-12-24 2013-08-26 Spinifex Pharm Pty Ltd Fremgangsmåde til behandling eller profylakse
MX2009003658A (es) * 2006-10-05 2009-04-22 Cv Therapeutics Inc Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
NZ579355A (en) * 2007-02-01 2012-03-30 Resverlogix Corp 2-(Aryl)-4-oxo-quinazoline derivatives
EP2131844A1 (en) * 2007-04-09 2009-12-16 CV Therapeutics Inc. PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS

Also Published As

Publication number Publication date
JP2010523674A (ja) 2010-07-15
IL201117A0 (en) 2010-05-17
RU2009141596A (ru) 2011-05-20
KR20100016421A (ko) 2010-02-12
BRPI0809551A2 (pt) 2014-09-16
AU2008239689A1 (en) 2008-10-23
EP2155695A1 (en) 2010-02-24
CN101652353A (zh) 2010-02-17
US20080255161A1 (en) 2008-10-16
WO2008127615A1 (en) 2008-10-23
CA2683925A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
MX2009010894A (es) Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
MX2009003658A (es) Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MX342423B (es) Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
AU2007221366A8 (en) Oxyntomodulin derivatives
MX2009012920A (es) Compuestos heptaciclicos y usos farmaceuticos de los mismos para la prevencion y tratamiento de diabetes y sindrome metabolico.
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
IL213425A0 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase
CO6341563A2 (es) Compuestos organicos
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
MX2010009883A (es) Acidos dicarboxilicos de cadena media, sus derivados y enfermedades metabolicas.